EGEGazette
Live
Report: Hurricane Polo hits Mexico: strong winds and flooding in Baja California SurReport: Russians strike school in Sumy with children sheltering inside — mediaReport: Hurricane Polo makes landfall on Mexico's Pacific coast, heads toward SonoraReport: Red alert in Catalonia: torrential rain floods the Penedès and cuts off metro and roads in BarcelonaIn brief: Myanmar: military air strike on market kills at least 50, humanitarian sources sayReport: Vessel struck by suspected projectile in Strait of HormuzReport: Fire breaks out on vessel hit by projectile in Strait of Hormuz: UK maritime agencyEthiopian Army Announces Control of Alamata Town in Tigray RegionStrong Explosions in Kyiv After Russian Ballistic Missile StrikesIn brief: Ethiopia: fighting intensifies between the TPLF and the federal army in TigrayMyanmar rebels report 49 killed in government troop strikesReport: Ethiopian army clashes with rebel alliance across multiple fronts
BusinessReported

Novo Nordisk shares drop as much as 7% despite $23 billion obesity drug sales target

The decline came even as the Danish drugmaker set an ambitious sales goal for its weight-loss treatments, CNBC reported.

· 1 min read · language: en

Shares of Novo Nordisk fell as much as 7% even after the company set a $23 billion sales target for its blockbuster obesity drugs, according to CNBC.

CNBC did not report a specific reason investors gave for the decline, noting only that the drop came despite the ambitious sales goal set by the Danish pharmaceutical company for its weight-loss treatments.

Sources

EGazette summarizes reporting from multiple sources; follow the links for the originals.

Comments

Sign in to join the conversation.

Forgot password?

No account?

Loading comments…

Related articles